Enara Bio
Develops cancer immunotherapies targeting unconventional antigens
$32.5M Series B+ ·
Source: Pharmaceutical Technology
Latest round on record: Series B+, June 2026, amount undisclosed.
All 2 rounds ↓Signals
X account@Enara_Bio · created Sep 10, 2019 (7 years old) · 304 followers
Website registeredFeb 27, 2020 (6 years old)
TIMELINE · MONEY RAISED
Enara Bio | 1850 days from X account to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
- Series B+ · amount undisclosedSource: fundraisingfox.com
- Series B+ · $32.5MSource: Pharmaceutical Technology
- Website created
- X account created
Founders and team
DP
Drew Pardoll Co-founder of Enara Biosource: enarabio.comGK
George Kassiotis Co-founder of Enara Biosource: enarabio.comHA
Houman Ashrafian Co-founder of Enara Biosource: enarabio.comKP
Kevin Pojasek President and CEOAF
Andrew Fadden Chief Business OfficerSD
Scott Drutman Chief Medical OfficerSD
Scott Druttman Chief Medical OfficerSD
Stacey Davis Chief Financial Officer
Investors
MM Ventures
PPfizer Venture Investments
RRA Capital Management
SSamsara Biocapital
SSV Health Investors
TThe Francis Crick Institute
Companies like Enara Bio
DDeepflareSeed · Jul 2022
CCrossbow Therapeutics$77M Series B+ · Mar 2026
TTacalyx$12.88M Seed · Apr 2026
AAsher Bio$55M Series B+ · Apr 2024
BBright Peak TherapeuticsSeries B+ · Aug 2026
FFoRx Therapeutics$50M Series A · Dec 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/enara-bio (get a free API key).